Bausch + Lomb to Present New Scientific Data and Analyses at the ASCRS Annual Meeting

Bausch + Lomb announced 15 podium and four poster presentations during the American Society of Cataract and Refractive Surgery (ASCRS) annual meeting, which will take place in Boston, April 5-8, 2024.

Podium presentations include the results of studies evaluating the new Teneo Excimer Laser Platform, enVista and IC-8 Apthera IOLs, and dry eye drug Miebo. Poster presentations include the results of Teneo and IC-8 Apthera IOL studies.

In addition to these scientific presentations, the company will also sponsor educational events focused on these and other Bausch + Lomb products.

Bausch + Lomb activities at ASCRS:

Podium Presentations

• “Assessment of the Spectacle Independence and Visual Outcomes Following Bilateral Implantation of a Novel Toric IOL* Among Cataract Patients.” Harasymowycz et al.
• “Binocularity and Stereoacuity in Modern Monovision with a Small-Aperture IOL.” Wiley et al.
• “Characterization of Discontinuation and Switching Patterns of Dry Eye Disease Medications Using Linked EHR Registry and Claims Data.” Mbagwu et al.
• “Clinical Results of Small-Aperture IOL Implantation Following Corneal Inlay Removal.” Ang et al.
• “Defocus Curve Performance of a Novel Hydrophobic Acrylic Trifocal Intraocular Lens*: A Prospective, Multicenter Canadian Study.” Muzychuk et al.
• “Early Real World Outcomes of Small Aperture IOL in Post Refractive Eyes.” Hu et al.
• “Outcomes of an Ultra-Low Cylinder Powered (0.90 D) Toric versus Non-Toric IOL in Low Astigmatic Patients Undergoing Cataract Surgery.” Muzychuk et al.
• “Patient-Reported Instillation Comfort and Eyedrop Acceptability of Perfluorohexyloctane Ophthalmic Solution in Pivotal Clinical Studies.” White et al.
• “Patient-Reported Outcomes Following LASIK, Performed Using a Novel Excimer Laser for the Correction of Myopia and Myopic Astigmatism.” Stonecipher et al.
• “Perfluorohexyloctane Ophthalmic Solution for Dry Eye Disease: Efficacy Among Various Participant Subgroups in Pivotal Clinical Trials.” Sheppard et al.
• “Predicted In-Vitro versus In-vivo Measurements of Higher-Order Corneal Aberrations following Apthera Implantation Post Radial Keratotomy.” Devaro et al.
• “Quality of Vision and Clinical Outcomes of a Novel Trifocal IOL* Implanted Bilaterally After Cataract Surgery: A Canadian Multicenter Study.” Harasymowycz et al.
• “Subjective versus Objective Depth of Focus from Ray-Tracing Aberrometry in Small Aperture Optics Intraocular Lens in Eyes with Aberrated Corneas.” Barros et al.
• “Visual and Refractive Outcomes following Bilateral Implantation of a Novel Trifocal* or Monofocal IOL: A Prospective, Multicenter US study.” Liang et al.
• “Visual Performance of Negative versus Neutral Aspheric Monofocal Intraocular Lenses: A Randomized Controlled Trial.” Kudrna et al.

Poster Presentations

• “Binocular Visual Outcomes and Defocus Curve of Bilaterally Implanted Novel Trifocal Intraocular Lens*: A Prospective, Multicenter US study.” Shultz et al.
• “Estimation of Visual Benefit with IC-8 in Keratoconus Patients.” Klyce et al.
• “Initial Results Using Small Aperture Optics IOL in Patients with or without Prior Ocular Surgery, Corneal Scarring or Irregular Astigmatism.” Shultz et al.
• “Outcomes of LASIK Performed Using the Updated Laser Ablation Algorithm for the Correction of Myopia and Myopic Astigmatism.” Chu et al.

Featured Educational Events

Friday, April 5

• “Rethinking Dry Eye Disease: A Contemporary Approach to a Complex Condition”
  7:15-9:15 p.m. ET at Davio's Seaport (26 Fan Pier, Boston)
  The program will feature the dynamic duo of Laura Periman, M.D., and Darrell White, M.D., who will discuss MIEBO and XIIDRA® (lifitegrast ophthalmic solution) 5%.

Saturday, April 6

• “Refractive Redefined: TENEO, the New FDA Approved Excimer Laser”
  3:00-3:50 p.m. ET in the at the Boston Convention & Exhibit Center (415 Summer Street, Boston; ASCRS Tap Room)
  Join George Waring IV, M.D., to learn more about the accuracy, efficiency and usability advantages of TENEO, the first excimer laser platform approved in nearly two decades.

• “Innovations in DED and Novel Cataract Surgery Technologies”
  6:30-8:00 p.m. ET at the Omni Boston at the Seaport (450 Summer Street, Boston; Momentum Ballroom, Level 5)
  Join moderator Eric Donnenfeld, M.D., along with presenters Marjin Farid, M.D., Ravi Patel, M.D., and Karl Stonecipher, M.D., to learn more about the benefits of and differences between MIEBO and XIIDRA, as well as the benefits of using the new enVista Aspire lens for doctors and their patients.

Sunday, April 7

• Innovator’s Session
  Featuring Andrew Stewart, President, Global Pharmaceuticals and International Consumer
  10:00am—11:30am, ASCRS Main Stage
  *enVista Envy is pending PMA approval and is not approved for sale in the United States or its territories